Publications by authors named "Svenja Neumann"

Claim this Profile
I
Implications of Regurgitative Feeding on Plastic Loads in Northern Fulmars (): A Study from Svalbard.
Felix Tulatz, Geir Wing Gabrielsen, Sophie Bourgeon, Dorte Herzke, Rupert Krapp, Svenja Neumann

Environ Sci Technol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ingested plastics in northern fulmars (Fulmarus glacialis): A pathway for polybrominated diphenyl ether (PBDE) exposure?
Svenja Neumann, Mikael Harju, Dorte Herzke, Tycho Anker-Nilssen, Signe Christensen-Dalsgaard

Sci Total Environ· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Controlling Spin-Correlated Radical Pairs with Donor-Acceptor Dyads: A New Concept to Generate Reduced Metal Complexes for More Efficient Photocatalysis.
Svenja Neumann, Oliver S Wenger, Christoph Kerzig

Chemistry· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative insights into charge-separated states from one- and two-pulse laser experiments relevant for artificial photosynthesis.
Svenja Neumann, Christoph Kerzig, Oliver S Wenger

Chem Sci· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fundamentally Different Distance Dependences of Electron-Transfer Rates for Low and High Driving Forces.
Svenja Neumann, Oliver S Wenger

Inorg Chem· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.
Nicola Gökbuget, Gerhard Zugmaier, Matthias Klinger, Peter Kufer, Matthias Stelljes, Svenja Neumann

Haematologica· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
Andreas Viardot, Marie-Elisabeth Goebeler, Georg Hess, Svenja Neumann, Michael Pfreundschuh

Blood· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
Gerhard Zugmaier, Nicola Gökbuget, Matthias Klinger, Andreas Viardot, Matthias Stelljes, Svenja Neumann

Blood· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Max S Topp, Nicola Gökbuget, Anthony S Stein, Gerhard Zugmaier, Susan O'Brien, Svenja Neumann

Lancet Oncol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
Max S Topp, Nicola Gökbuget, Gerhard Zugmaier, Petra Klappers, Matthias Stelljes, Svenja Neumann

J Clin Oncol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.
Max S Topp, Nicola Gökbuget, Gerhard Zugmaier, Evelyn Degenhard, Marie-Elisabeth Goebeler, Svenja A Neumann

Blood· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
Matthias Klinger, Christian Brandl, Gerhard Zugmaier, Youssef Hijazi, Ralf C Bargou, Svenja Neumann

Blood· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Max S Topp, Peter Kufer, Nicola Gökbuget, Mariele Goebeler, Matthias Klinger, Svenja Neumann

J Clin Oncol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of apoptosis in PanIN-1 and PanIN-2 lesions associated with pancreatic ductal adenocarcinoma is not dependent on K-ras status.
Jutta Lüttges, Svenja Neumann, Ralf Jesenofsky, Vivian Borries, Matthias Löhr

Pancreas· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis